Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT00002881 Completed - Prostate Cancer Clinical Trials

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Start date: October 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Hormone therapy may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to evaluate the effectiveness of treatment with flutamide and suramin with or without hydrocortisone in men who have metastatic or recurrent prostate cancer.

NCT ID: NCT00002874 Completed - Prostate Cancer Clinical Trials

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Start date: February 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective with or without bicalutamide for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide in treating patients who have stage II or stage III prostate cancer and elevated prostate-specific antigen (PSA) levels following radical prostatectomy.

NCT ID: NCT00002855 Completed - Prostate Cancer Clinical Trials

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Start date: August 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.

NCT ID: NCT00002848 Completed - Prostate Cancer Clinical Trials

Group Therapy Compared With Educational Materials in Patients With Prostate Cancer

Start date: April 1997
Phase: N/A
Study type: Interventional

RATIONALE: Developing coping strategies may help improve the quality of life of patients with prostate cancer. PURPOSE: This randomized clinical trial is comparing the effect of group therapy with written educational materials on the quality of life of men with stage I or stage II prostate cancer.

NCT ID: NCT00002775 Active, not recruiting - Prostate Cancer Clinical Trials

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Start date: February 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.

NCT ID: NCT00002760 Completed - Prostate Cancer Clinical Trials

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

Start date: August 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men with prostate cancer that is refractory to hormone therapy.

NCT ID: NCT00002723 Completed - Prostate Cancer Clinical Trials

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Start date: January 1996
Phase: Phase 3
Study type: Interventional

Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of suramin is more effective for prostate cancer.

NCT ID: NCT00002721 Completed - Prostate Cancer Clinical Trials

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Start date: March 1995
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.

NCT ID: NCT00002703 Completed - Prostate Cancer Clinical Trials

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Start date: January 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation therapy with high-dose radiation therapy in treating men with stage I or stage II prostate cancer.

NCT ID: NCT00002677 Completed - Prostate Cancer Clinical Trials

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

Start date: August 1995
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of tributyrin in treating patients with refractory stage IV prostate cancer or other solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.